Group 1 - The core viewpoint of the article is that Meili Tianyuan Medical Health (02373) is experiencing a significant stock price increase, with a rise of nearly 5% and a current price of 26.5 HKD, driven by positive financial forecasts [1] - The company anticipates achieving a revenue of no less than 3 billion RMB in 2025, representing a year-on-year growth of at least 16% [1] - Adjusted net profit is expected to be no less than 380 million RMB, with a year-on-year increase of at least 40%, while net profit is projected to be no less than 340 million RMB, reflecting a year-on-year growth of at least 34% [1] Group 2 - The board attributes the performance improvement primarily to accelerated external expansion, including the acquisition of the second-ranked brand in China's beauty industry, Nairui'er, which enhances market share and boosts revenue and profit [1] - Strong organic growth is noted, with an increase in brand momentum and customer numbers driving internal revenue growth, alongside a higher proportion of high-margin medical business revenue [1] - The release of operational efficiencies through refined management practices is also contributing to further profit margin growth [1]
港股异动 | 美丽田园医疗健康(02373)涨近5% 预期2025年经调整净利润同比增长不少于40%